

Special Issue

New and Emerging Targeted Topical and Systemic Drugs for Immunemediated Cutaneous Diseases

Message from the Guest Editor

Immune-mediated cutaneous diseases are a group of disorders that arise due to abnormal immune system functioning, affecting a significant number of individuals worldwide. These diseases can significantly impact patients' quality of life and cause physical and emotional distress. This Special Issue aims to review new and emerging therapies for immune-mediated cutaneous diseases, including psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa. Articles focused on the latest advances in targeted therapies, as well as promising therapies in development, including novel small molecules and biologic agents, are welcome. Our goal is to provide clinicians and researchers with a comprehensive understanding of the current state of the art in the treatment of these conditions.

- psoriasis
- atopic dermatitis
- alopecia areata
- vitiligo
- hidradenitis suppurativa
- prurigo nodularis
- urticaria
- cutaneous lupus
- drug targeting

Guest Editor

Prof. Dr. Tiago Torres

1. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

Deadline for manuscript submissions

closed (31 October 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/170931

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).